At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 17, 2026 at 07:42 ET
Tango Therapeutics is holding its annual shareholder meeting to vote on the re-election of three Class II directors, ratification of its auditor, and approval of executive compensation. This is a routine annual proxy filing, and recent executive changes suggest ongoing leadership transitions.
- Shareholders will vote on the re-election of directors Malte Peters, M.D., Kanishka Pothula, and Mace Rothenberg, M.D.
- The board recommends ratifying PricewaterhouseCoopers LLP as the independent auditor.
- The board recommends approving the compensation of named executive officers.
- Recent executive changes include the appointment of Matthew Gall as CFO and Jessica Newcomb as principal accounting officer.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access